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Circadian dysfunction has been described in patients with symptomatic Alzheimer’s
disease (AD), as well as in presymptomatic phases of the disease. Modeling this
circadian dysfunction in mouse models would provide an optimal platform for
understanding mechanisms and developing therapies. While numerous studies have
examined behavioral circadian function, and in some cases clock gene oscillation,
in mouse models of AD, the results are variable and inconsistent across models,
ages, and conditions. Ultimately, circadian changes observed in APP/PS1 models are
inconsistent across studies and do not always replicate circadian phenotypes observed
in human AD. Other models, including the 3xTG mouse, tau transgenic lines, and
the accelerated aging SAMP8 line, show circadian phenotypes more consistent with
human AD, although the literature is either inconsistent or minimal. We summarize these
data and provide some recommendations to improve and standardize future studies of
circadian function in AD mouse models.
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INTRODUCTION
Numerous human studies have demonstrated that changes in circadian function are common in
Alzheimer’s disease (AD) patients and contribute to disease morbidity. Circadian changes observed
in AD patients include circadian fragmentation and decreased amplitude of circadian rhythms,
which generally manifest as increased wakefulness at night and increased napping during the
day (Satlin et al., 1995; Ancoli-Israel et al., 1997). These changes are observed in patients with
preclinical AD pathology, meaning that they harbor amyloid plaque and/or tau pathology but
do not yet have cognitive symptoms (Musiek et al., 2018). They are also evident in the mild
cognitive impairment stage and worsen with disease severity. In symptomatic AD patients, a
phase delay has been described, which means that the peak of activity occurs later in the day
(Satlin et al., 1995; Ancoli-Israel et al., 1997). This phase delay has been hypothesized as a possible
cause of “sundowning” in AD, or increased confusion and agitation in the afternoon and evening
(Volicer et al., 2001). As the disease progresses, some patients develop severe fragmentation of
circadian rhythms, leading to poor behavioral differentiation between day and night (Ancoli-Israel
et al., 1997; Hatfield et al., 2004). The underlying mechanisms governing this circadian dysfunction
Abbreviations: Aβ, amyloid-beta peptide; AD, Alzheimer’s disease; ApoE, apolipoprotein E; APP, amyloid precursor protein;
DD, constant darkness; LD; 12 h light:dark cycle; IV, intradaily variability; PS1, presenilin 1; SAMP8, senescence accelerated
mouse P8; SCN, suprachiasmatic nucleus; 3xTG, APP/PS1/tau triple transgenic mouse.
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are not well understood, creating a need for accurate mouse
models which replicate some of these phenotypes.
Circadian biology can be a daunting field for AD researchers.
Thus, a brief introduction to common circadian parameters may
be helpful (Banks and Nolan, 2011). Circadian period is the
length of time of a full circadian cycle. This can only be measured
under “constant conditions” (usually meaning constant darkness
for mice, indicated as “DD”). Most mice have a period just
under 24 h in constant darkness; shortening or lengthening
of period can be indicative of changes in the circadian clock
itself. Amplitude indicates the difference between the peak and
nadir of activity, averaged over several days. In general, mice
should have minimal activity during the light phase (as they are
nocturnal and sleeping), but are very active during the dark phase.
Increased activity during the light phase and decreased activity in
the dark would indicate blunted circadian amplitude, as is seen
in AD patients. However, generally hyperactive animals can be
overactive during the dark phase and have a high amplitude,
while hypoactive animals may be inactive during both phases
and show artificially blunted amplitude. If these differences in
baseline activity levels are altered in transgenic mouse models, it
may lead to difficulty interpreting circadian behavioral analyses.
Phase indicates the time of day of peak activity, averaged over
several days. A later peak (phase delay) is seen in AD patients.
Fragmentation indicates a breakdown of circadian timing to
drive consolidated periods of rest and activity. Fragmentation
usually leads to a blunted amplitude, or can be measured by
a non-parametric test called intradaily variability (IV) (Huang
et al., 2002). Of note, circadian rhythms in behavior are largely
driven by the activity of the suprachiasmatic nucleus (SCN) of
the hypothalamus, the “master clock” of the body. Degeneration
or dysfunction of the SCN, as has been described in human AD
(Swaab et al., 1985), can lead to weaker circadian synchronization,
increased fragmentation, and decreased amplitude (Nakamura
et al., 2011). At a molecular level, circadian rhythms are driven
by oscillations of circadian clock genes in the SCN and other
tissues. These circadian clock genes include Bmal1 and Clock,
which function as transcription factors to drive transcription of
their own repressors: Per1, Per2, Per3, Cry1, Cry2, and Rev-erbα
and β. Levels of these clock gene transcripts oscillate with a 24-
h period in most tissue and are entrained to daily light cycles
(Buhr and Takahashi, 2013). Thus, measurement of clock gene
oscillations in SCN and other tissues can be a molecular marker
of clock function.
Over the past 20 years, a considerable literature has arisen in
which circadian parameters have been examined in various AD
models. Many of these studies have described modest changes in
AD model mice, though these changes vary considerably between
studies. The sheer number of distinct AD mouse models, as well
as the age- and sex-dependency of pathology in these models, has
complicated things further. Thus, it remains difficult to identify
AD models which consistently and faithfully recapitulate the
findings observed in human AD. Below, we have attempted to
divide AD mouse models into their most common categories,
and to review the existing literature on circadian rhythms in
these models. These data are compiled in Table 1. While not an
exhaustive or systematic review, the included studies represent
many of the vast majority of published studies, as well as the
most commonly cited and most thorough studies of circadian
function in AD mouse models (other species were excluded),
and thus provide what we believe is a representative sample
of the literature.
APP and APP/PS1 Mice
There are a multitude of different transgenic mouse lines which
express human amyloid precursor protein (APP) and in some
cases human presenilin 1 (PS1), both harboring a variety of
AD-associated mutations which promote amyloid-beta (Aβ)
generation and aggregation. These mice accumulate amyloid
plaque pathology at variable ages and in varying brain regions
depending on the specific transgene and sex of the animal.
APP/PS1 mice also vary in the biochemical character of the
plaques that are formed, as well as the presence or absence
of intracellular amyloid. Presumably, APP and APP/PS1 mice
model the earliest stage of AD, that being amyloid plaque
deposition, as most of these models develop minimal tau
pathology or overt neurodegeneration. Humans with preclinical
AD or MCI have been shown to have decreased circadian
amplitude, increased fragmentation, and, in MCI, a phase delay
(Naismith et al., 2014; Ortiz-Tudela et al., 2014). However, results
of circadian studies in APP and APP/PS1 mice do not clearly
demonstrate consistent AD-like phenotypes. Several studies have
shown increased activity in these mouse lines during the dark
phase (the active phase of mice), as well as increases in circadian
amplitude (Ambrée et al., 2006; Bedrosian et al., 2011; Baño
Otalora et al., 2012; Oyegbami et al., 2017). Aside from this, the
wide variety of subtle and oft-conflicting circadian phenotypes
in APP and APP/PS1 mouse studies can be appreciated in
Table 1. Thus, a clear circadian phenotype which models early
human AD has not emerged from the literature. Recently, Kent
et al. conducted a very thorough study of APPswe/PS1dE9 mice,
a commonly used APP/PS1 model which developed plaques
around 6 months old (mo). This study, which examined mice at
multiple ages and included a variety of light manipulations and
Per2-luciferase rhythm recordings in SCN and various peripheral
tissues (such as liver, lung, and spleen), revealed only a minimal
delay in activity onset after lights-off in transgenic mice (Kent
et al., 2019). Moreover, several studies demonstrate circadian
changes which precede amyloid plaque pathology, suggesting
possible strain or transgene effects, though an effect of soluble
Aβ cannot be excluded (Bedrosian et al., 2011; Ortiz-Tudela
et al., 2014; Oyegbami et al., 2017; Ni et al., 2019). While not a
true circadian study, Roh et al. (2012) demonstrated blunting of
amplitude in diurnal rhythms in sleep and brain lactate levels in
APPswe/PS1dE9 mice, which was reversible with immunization
of an anti-Aβ antibody, suggesting that amyloid pathology may
indeed contribute to some aspects of rhythm dysfunction. Paul
et al. (2018) examined the TgSwDI APP mutant mouse and
observed shortened period and increased variability in activity
onset/offset that were associated with blunted amplitude of
neuronal firing in the SCN, providing an electrophysiological
basis for rhythm disturbance. A human BACE1 knockin mouse,
which drives intracellular amyloid accumulation without APP
overexpression, showed decreased dark-phase activity but no
























TABLE 1 | Summary of studies of circadian function in mouse models of AD.
Citation/PMID Mouse model Age Conclusions/effects observed DD Comments
Oyegbami et al., 2017 28317486 APPswe/PS1dE9 2 months Transgenic (Tg) mice have increased daily activity and increased
activity amplitude with a slightly shorter period. Cry1 and Cry2
expression seems blunted in the medulla pons at ZT2 and ZT14
Yes No pathology shown. Measurements
are taken before pathology should be
present. Difficult to tell whether
oscillations in clock genes are blunted
with only two time points
Baño Otalora et al., 2012 22823866 APPswe/PS1dE9 3.5–5.5 months Response to phase shifting paradigms was not altered in Tg mice.
Body temperature increased in the light phase in Tg mice and
intradaily variability of body temperature was not affected. Tg mice
showed no difference in period or locomotor activity
Yes No pathology shown. Measurements
are taken before pathology should be
present
Kent et al., 2019 30884411 APPswe/PS1dE9 6, 9, 12, and 19 months No difference in period, response to phase shifting, total daily
activity, melanopsin expression, ultradian rhythms, intradaily
variability, number or duration of activity bouts, food anticipatory
behavior, synchrony in peripheral oscillators or total time spent
asleep. Tg mice have slightly delayed activity onset and exhibit
increased activity in the second half of the night
Yes Pathology was only shown at 7 and 10
months of age and was not correlated
to circadian parameters assessed
Ma et al., 2016 27796320 APPswe/PS1dE9 12–15 months Per2 and Cry1 mRNA amplitudes decreased in hippocampus in Tg
mice sampled at 6-h time intervals
No mRNA rhythms were not quantified.
Age is appropriate to have plaque
pathology
Paul et al., 2018 29540298 tg-SwDI (APP
mutant)
3, 6, 10 months Tg mice with shortened period in DD, more variable activity
onset/offset. SCN neuronal firing amplitude decreased (less during
day, more during night)
Yes SCN electrical records are unique. No
pathology shown
Ni et al., 2019 31470863 APP-KI 2 months Isolated cortical microglia from 2-month-old Tg mice at 4-h time
intervals have less Bmal1, Per2, and Rev-erbα on average.
Amplitude of most clock genes were decreased in these microglia
No Did not show pathology. Mice this
young should not have disease
pathology
Bedrosian et al., 2011 21709248 Tg2576 (APPswe) 5 and 9 months Increased daily activity in the dark phase in Tg mice No No constant conditions or pathology
shown
Wisor et al., 2005 15708480 tg2576 (APPswe) 5–17 months Age-dependent increase in period in DD. No other circadian
analyses
Yes No pathology shown
Sundaram et al., 2019 31551449 APPSwe crossed
with PS1 line 5.1
9–10 months Tg mice have a slightly shorter period in DD and increased intradaily
variability. No difference in overall activity observed but Tg mice had
an increased activity amplitude at the peak of the active cycle which
did not persist in DD
Yes
Duncan et al., 2012 22634208 APPNLH/PS-1P264L 4, 11, and 15 months Tg mice show no difference in activity rhythms. VIP and vasopressin
were not altered in the SCN. No change in AM/PM Per2 expression
in the hippocampus, cingulate or motor cortex, but blunted PM
Per2 expression in SCN of Tg mice. Amount of wheel running
activity in the light phase was significantly decreased in Tg mice
No Showed pathology at all time points
using an Aβ ELISA. No constant
conditions
Lee et al., 2020 31800167 5x FAD (APP/PS1) 6.5 months BMAL1 protein is decreased in the cortex of Tg mice. Per2 mRNA
is decreased in the hippocampus and cortex of Tg mice while Per1
is only shown to decrease in the hippocampus
No Only checked expression level at a










































TABLE 1 | Continued
Citation/PMID Mouse model Age Conclusions/effects observed DD Comments
Song et al., 2015 25888034 5x FAD (APP/PS1) 2 and 8 months Tg mice have decreased activity at 8 months of age and decreased
body temperature amplitude that persists in DD. Protein levels and
mRNA expression of Bmal1 and Rev-erbα are altered in the SCN of
2-month-old Tg mice measured at 4-h intervals. BMAL1 protein
rhythms are blunted
Yes No rhythmic analysis on mRNA or
protein measurements. No pathology
shown. mRNA analysis was done
before pathology should be present
Boggs et al., 2017 28958954 J20 APP/Apoe4 6 and 12 months Activity onset was delayed in Tg mice at 6 and 12 months of age.
Tg mice show decreased activity in the light phase at 12 months of
age and no difference in activity in the dark phase
No No pathology shown
Ambrée et al., 2006 15993515 TgCRND8 30, 60, 90, 120 days Increased daily activity in Tg mice at all ages No No constant conditions and no
pathology shown. Circadian changes
occur before pathology is likely present
Adler et al., 2019 31334659 3xTG-AD 10–11 months Tg mice have a slightly shorter period in DD and displayed irregular
activity onsets
Yes No pathology shown
Knight et al., 2013 22864021 3xTG-AD 4, 6, 8, 9, 10 months Tg mice have a higher body temperature amplitude as they age.
Increase in activity amplitude not seen until mice are 10 months of
age. No pathology seen in the hypothalamus of 12-month-old Tg
mice
No No constant conditions and pathology
is only shown at one time point (12
months old)
Wu et al., 2018 29626648 3xTG-AD 6 months Tg mice have a slightly shorter period with a lower daily activity and
a smaller activity amplitude. Tg mice also have an increase in
intradaily variability. Per1 and Per2 mRNA in the SCN seem to have
a phase delay of 4 h in Tg mice
Yes Never show differences in pathology, no
statistical analysis of rhythms or phase.
mRNA not harvested under DD
Bellanti et al., 2017 28671110 3xTG-AD 6 and 18 month old Examine mRNA of several clock genes in SCN, hippocampus, and
frontal cortex of 3xTG mice, at lights on (ZT0, 7 am) or lights off
(ZT12, 7 pm). Two ages assessed. Blunting of Bmal1 expression in
the SCN, along with some other changes in clock gene expression
in older mice
No No constant conditions, cannot
differentiate effects of light exposure
from those of circadian time. Multiple
brain regions and ages is a strength
Sterniczuk et al., 2010 20471965 3xTG-AD Various Tg male mice have elevated light and dark phase activity, not
age-dependent. Female Tg mice post-plaque pathology show
decreased activity during dark. Shorter period in males only in DD.
Male Tg mice have fewer AVP and VIP cells in the SCN (females not
assessed). No difference observed in response to phase shifting
Yes Only period is assessed in DD. No
pathology shown outside of SCN,
although SCN pathology and sex
discrimination is a strength
Stevanovic et al., 2017 28461004 Tg4510 Tau 8 months Tg mice have a longer free running period and are more active in the
light phase, which does not persist in constant conditions. PER2
protein is decreased in the hypothalamus and hippocampus of Tg
mice at two time points, with no difference in BMAL1 expression.
Phosphorylated tau is present in the SCN at 8 months of age
Yes Only checked at one age-unclear if
these effects are due to the progression
of pathology. Harvest of tissue in DD is
a strength. Difficult to make conclusions
of Bmal1 and Per2 oscillations with only
two time points
Miyamoto et al., 1986 3786521 SAMP8 2,6,8,12 months Tg mice have increased activity in the light phase and decreased in
dark phase, decreased amplitude
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other major circadian alterations, though assessment was limited
(Plucinska et al., 2014). An issue with the wide array of APP
and APP/PS1 is that these transgenes are driven by specific
promoters (including the Thy1 and prion protein promoters)
which may not express in all relevant cell types and regions (such
as the SCN and circadian output pathways). This variability of
transgene expression may account for some of the inconsistency
in circadian phenotypes across APP/PS1 models. While APP and
APP/PS1 models have been the most studied in terms of circadian
function, the wide array of unique APP and APP/PS1 lines, as well
as the possible amyloid-independent effects of these transgenes
on activity level, has led to a murky literature which undermines
the utility of these models for examining circadian changes.
Tauopathy Models
Tau transgenic mice overexpress the human MAPT gene with
disease-causing mutations (often P301S or P301L) and are often
used to model tauopathy associated with AD. Unlike APP mice,
tau transgenics generally develop striking neurodegeneration
and premature death. The Tg4510 mouse, an aggressive model
of tauopathy which expresses MAPTP301L (Ramsden et al.,
2005), develops a lengthened circadian period and decreased
circadian amplitude, as well as seemingly blunted circadian clock
gene expression in the hypothalamus and hippocampus when
measured at two times of day (Stevanovic et al., 2017). These
changes were observed at 8 mo, when severe tau pathology is
present. SCN tau pathology was also noted in this study. A study
of MAPTP301S PS19 mice, which focused exclusively on sleep,
showed a decrease in sleep and an increase in wakefulness,
suggesting a possible underlying circadian deficit, very late in the
disease progression (Holth et al., 2017). While promising, further
studies of circadian function in tauopathy models are needed to
determine how robust and consistent these changes are across tau
models and studies.
3xTG Mice
The 3xTG mouse was introduced in 2003 as a murine model of
both of the hallmark neuropathologies of human AD: amyloid
plaques and tau tangles. 3xTG mice express three transgenes
(APP Swedish, MAPT P301L, and PS1 M146V) and develop
amyloid plaque pathology starting around 4 months, with
aggregated tau pathology beginning around 12 months (Oddo
et al., 2003). Several studies have examined circadian function
in 3xTG mice, some of which describe phenotypes which
more closely resemble human AD. However, results are fraught
with inconsistency across different studies. Wu et al. (2018)
show a striking decrease in amplitude, less daily activity, and
fragmentation (increased IV) in 6 mo 3xTG mice, reminiscent
of human AD circadian dysfunction. Knight et al. (2013) report
no changes in activity profile in 6 mo 3xTG mice and go on to
show an increased amplitude in daily activity and temperature
rhythm by 10 months. Moreover, Sterniczuk et al. (2010) show
increased amplitude and daytime activity in four month old
male mice while female mice show a decreased amplitude by 11
months. Finally, Adler et al. (2019) showed a shortened period
and decreased amplitude in 3xTG mice which was ameliorated
by inhibiting casein kinase 1δ and 1ε, enzymes that are important
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for the degradation of PER proteins and maintenance of core
clock function. Thus, while the 3xTG mouse shows some promise
as a more accurate model of AD-like circadian changes, the
inconsistency across studies makes interpretation difficult. It is
also notable that these circadian changes were all observed at
ages prior to the accumulation of considerable tau pathology.
Of note, a different triple-transgenic mouse expressing APP,
hTau, and PS1, specifically in the forebrain (PLB1 mice), did not
show obvious circadian deficits, suggesting that SCN-dependent
expression of pathology may be important (Platt et al., 2011).
Other AD Models
The Senescence Accelerated Mouse, line P8 (SAMP8 mouse) is
a unique, non-transgenic mouse line that has been selectively
bred to promote accelerated aging (Butterfield and Poon, 2005;
Ramsden et al., 2005; Holth et al., 2017; Stevanovic et al., 2017).
SAMP8 mice are usually compared to another SAM mouse
line which is aging-resistant (SAMR1) as a control. SAMP8
mice spontaneously develop mild amyloid-beta accumulation,
mild tauopathy, synapse loss, and cognitive impairment early
in life, and have been used as a model of AD (Morley et al.,
2012). SAMP8 mice show striking circadian changes, including
increased activity during light phase, decreased circadian
amplitude, and fragmentation (Miyamoto et al., 1986; McAuley
et al., 2002; Pang et al., 2004), although this has not always
been reported (Sánchez-Barceló et al., 1997). Like APP mice,
they show a general hyperactivity phenotype, which complicates
interpretation. However, the striking circadian changes observed
in several studies suggest that SAMP8 mice have potential as a
model of age and AD related circadian dysfunction.
Apolipoprotein E (ApoE) genotype is the major genetic risk
factor for sporadic AD, with the E4 allele imparting increased
risk. Apoe−/− mice have been reported to have more variable
activity rhythms in DD, impaired entrainment, and alterations
of SCN clock gene expression rhythms (Zhou et al., 2016).
However, APP mice expressing human ApoE4 do not have
more severe circadian changes than APP with wild type mouse
ApoE (Graybeal et al., 2015; Boggs et al., 2017). This is an
unexpected finding, as ApoE4 increases amyloid pathology in
mice (Castellano et al., 2011) and might be expected to exacerbate
circadian dysfunction. More detailed studies which incorporate
pathology assessments are needed. Injection of Aβ peptide into
the brain of wild type mice has also been used to model AD,
and has been reported to lengthen period and blunt clock
gene rhythms in the SCN (Navigatore-Fonzo et al., 2017), and
to alter expression patterns of Apoe and other mRNAs in
the hippocampus (Wang et al., 2016), though this model is
not widely used.
Impact of AD Pathology on Clock Gene
Expression
Differences in circadian outputs at the level of sleep-wake cycles
can generally be correlated to changes in the molecular clock.
However, differences in clock gene expression in studies of AD
models are generally difficult to interpret. For example, some
studies have suggested decreased expression of clock genes in AD
models before the onset of pathology. Oyegbami et al. (2017)
show a decrease in Cry1 and Cry2 in the medulla pons of 2-
month-old APPswe/PS1dE9 mice, while Ni et al. (2019) show
a decrease in Bmal1, Per2, and Rev-erbα in isolated cortical
microglia from 2-month-old APP-KI mice (both well before
plaque deposition occurs). Song et al. (2015) showed blunting
of rhythmic BMAL1 protein levels prior to disease pathology
in the SCN of 2 mo 5xFAD mice (an APP/PS1 mutant model).
These may indicate an effect of soluble Aβ, or effects of the
transgene/mutation introduced, highlighting the importance of
these assays at multiple ages over the course of disease pathology.
Wu et al. (2018) showed a slight phase delay and decreased
expression of Per1/2 in the SCN of 3xTG mice, while Ma et al.
(2016) showed altered rhythms in hippocampal Bace2 and Apoe
mRNA. Other studies in AD models have examined clock gene
expression at one or two time points throughout the circadian
cycle, usually early morning and early evening, in some case
showing a loss of variation in AD mice (Duncan et al., 2012;
Bellanti et al., 2017; Stevanovic et al., 2017; Lee et al., 2020). While
these can be used to make general conclusions, it is difficult to
interpret if clock genes are changing amplitude, or if there is
just a difference in phase of expression of that particular gene.
Detailed time courses of circadian gene expression in different
brain regions of AD mouse models at pathology-bearing ages are
needed to thoroughly address this issue.
Recommendations for Circadian Studies
in AD Mouse Models
Considering the complexity of this literature, we offer here some
recommendations for future studies of circadian rhythms in AD
mouse models:
Constant conditions: Mouse activity must be recorded under
constant conditions (usually constant darkness or dim light)
in order to make firm conclusions about the circadian system.
Many studies of behavioral rhythms in AD model mice are
conducted in 12:12 h light:dark, which introduces factors related
to light intensity, as well as the issue of “masking,” or behavioral
suppression by light which occurs independently of the circadian
system. Furthermore, previous studies have shown some rhythm
abnormalities in AD models in 12:12 h light:dark cycles that
resolve in constant conditions (Stevanovic et al., 2017; Sundaram
et al., 2019). Moreover, tissue harvests for clock gene expression
studies should also be conducted in DD, as light can impact clock
gene expression (Moriya et al., 2000).
Correlation with pathology: Many studies of circadian function
in AD models do not describe or quantify the degree of
pathology in their mice. It is important to demonstrate the
degree of pathology (amyloid plaque burden, tau pathology,
etc.) in the mice at the same age and in the same sex that
are used for behavioral studies. While previous papers can
be used as general guidelines, mice of a similar genotype
can have very different pathology when raised in different
colonies and facilities. Moreover, circadian deficits arising in
AD mice well before pathology may suggest behavioral effects
of transgene overexpression, rather than true pathology-driven
changes. Indeed, behavioral changes in 3xTG can be dependent
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on genetic background (Pardossi-Piquard et al., 2016). Finally,
it is potentially important to assess the degree of pathology
in the SCN in these mouse models, to see if there is a direct
effect on the central pacemaker. SCN pathology has only been
analyzed in a few models, as 3xTG mice do not have plaques
or tangles at 12 months, while Tg4510 mice do have SCN tau
pathology at 8 months (Knight et al., 2013; Stevanovic et al.,
2017). Even in the absence of clear plaque pathology, it is possible
that soluble Aβ species (such as oligomers) may impact SCN
function, though levels and dynamics of soluble Aβ species in
the SCN have not been examined. Finally, human post-mortem
AD SCN generally shows neuronal loss and tau pathology, rather
than plaques, which may not be recapitulated in amyloid-based
models (Stopa et al., 1999).
Multiple endpoints: Most studies focus on rhythms in wheel
running as the primary endpoint. While some have included
temperature or some limited clock gene investigation, little
is known about other circadian endpoints. Peripheral clocks,
for instance, could be disrupted even in the face of normal-
appearing wheel running behavior. Some studies do examine
Per2-luciferase rhythms in SCN explants (Kent et al., 2019), clock
gene expression in SCN (Song et al., 2015; Stevanovic et al., 2017),
or SCN firing rate (Paul et al., 2018). Integration of multiple
endpoints in future studies may reveal important phenotypes.
Sex and age considerations: Sex has a strong effect on both
circadian rhythms, as well as on pathology in AD models.
In general, female APP and APP/PS1 mouse lines develop
amyloid plaques faster than males, while this relationship is
reversed for the accumulation of tau pathology in MAPT mice
(Carroll et al., 2010; Sun et al., 2020). Furthermore, there is
potentially conflicting effects of sex on circadian biology that
could further complicate these studies (Bailey and Silver, 2014).
Thus, sex must always be considered. Age also has strong effects
on circadian function, but is less clearly tied to amyloid/tau
pathology in mouse models, as specific transgene/mutations can
drive pathology at vastly different ages. In some cases, mice
develop plaques when they are still young, while in others age and
amyloid pathology come together and may interact (Wisor et al.,
2005). Thus, the effects of age itself, and the rate of pathology
accumulation, must be considered.
CONCLUSION
In summary, while many AD mouse models exhibit alterations
in circadian behavioral rhythms and/or gene expression, these
changes are generally not consistent across studies or models,
or have questionable relevance to human AD. As such, it is
still unclear if specific protein pathologies (such as amyloid or
tau aggregation) directly drive circadian changes, or if these
observed changes are due to other factors (such as transgene
overexpression, genetic background, sex, or age). As new AD
models are developed, circadian studies must consider basic
study design principles, degree of pathology, age, and sex, in
order to provide interpretable and consistent results.
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